A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug ...

In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years.

The nasal spray had to go through many rounds of clinical testing, with some shown to improve depression, while others showed no improvement over a placebo. In 2019, the FDA approved Spravato for ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment ...

The company is developing psychedelics for depression, and hopes to go public within a year of its next published results, per documents seen by BI.

Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult patients. KLOXXADO ...

Free naloxone nasal spray is offered in Ontario, Quebec, the Yukon and Northwest Territories. Unlike the more invasive injectable version, the overdose-reversing medication is sprayed directly ...

A nasal spray, referred to as nasal anti-CD3 ... “It goes beyond their discharge, with all the spectrum of PTSD, anxiety, depression, and cognitive decline.” Following successful trials ...

Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult patients. KLOXXADO ® ...